FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

Linda Rider

Drug Safety Conversation (PDF – 166 KB) 11-22-2022 Fda Drug Safety Interaction The U.S. Foodstuff and Drug Administration (Fda) is investigating the threat of intense hypocalcemia with critical outcomes, such as hospitalization and demise, in clients with superior kidney disorder on dialysis treated with the osteoporosis drugs Prolia (denosumab). Our […]

Evaluation the effects of red yeast rice in combination with statin on lipid profile and inflammatory indices; a randomized clinical trial | BMC Nutrition

Linda Rider

Supplied the detrimental effects of dyslipidemia and in light of sure restrictions to statin use, this randomized medical demo (RCT) sought to assess the outcomes of crimson yeast rice (RYR) in individuals with dyslipidemia currently on statin remedy. We identified that RYR, together with statin remedy, can appreciably lower complete […]